This week’s buy-write trade is on Intra-Cellular Therapies (ITCI).  The stock dropped some 25% in a knee jerk fashion earlier last week as it disclosed some trial results that disappointed investors.  The shares are recovered a bit, but still appear oversold given the key catalyst the company has on the horizon.  We take a look at this week's news, why there should be upside in this name in coming months and an options strategy that can set up a great potential return while mitigating considerable downside risk.

DOWNLOAD FREE REPORT AT → https://www.bretjenseninvests.com/freereports

Comments


Bret Jensen
EditorBret Jensen
Bret Jensen
EditorBret Jensen
alexandra
Editoralexandra
New Comment
1
Bret Jensen
EditorBret Jensen
New Comment
1
Bret Jensen
EditorBret Jensen
New Comment
Bret Jensen
EditorBret Jensen
New Comment
alexandra
Editoralexandra
New Comment